Literature DB >> 9111185

Chlamydial pelvic inflammatory disease.

J Paavonen1, M Lehtinen.   

Abstract

Pelvic inflammatory disease (PID) is the most important complication present in the female lower genital tract, causing major medical, social and economic problems. Although PID can be caused by multiple microorganisms, it results most frequently from the ascent of sexually transmitted Chlamydia.trachomatis or Neisseria gonorrhoeae infections from the cervix to the upper genital tract. The importance of cervical chlamydial infection in the pathogenesis of PID is well recognized. Recent data from many developed countries have shown a striking decrease in the incidence of gonococcal infections, while the rates of chlamydial infections remain high in most countries. Complications of PID are common and usually irreversible. Emerging evidence suggests that universal or selected screening of defined populations for cervical chlamydial infection leads to a dramatic reduction in the incidence of PID. Recent technological advances should further enhance efforts to prevent chlamydial infection and PID. Gene amplification-based diagnostic tests, screening by testing first-void urine, and single dose antimicrobial therapy greatly facilitate chlamydia control programmes. Thus, screening for chlamydia is the key approach in the secondary prevention of PID. The obvious challenge is to make screening for chlamydia the standard for health care for young, sexually active individuals. Since PID is the most important consequence of sexually transmitted bacterial infections, it is also imperative to develop better treatments to prevent the long-term sequelae of this disease. The development and implementation of new and effective intervention programmes for prevention and control of PID is one of the major challenges for the year 2000 and beyond.

Entities:  

Mesh:

Year:  1996        PMID: 9111185     DOI: 10.1093/humupd/2.6.519

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  15 in total

1.  Evidence based health policy report. Screening for genital chlamydial infection.

Authors:  J Pimenta; M Catchpole; M Gray; J Hopwood; S Randall
Journal:  BMJ       Date:  2000-09-09

Review 2.  Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies.

Authors:  E Honey; C Augood; A Templeton; I Russell; J Paavonen; P-A Mårdh; A Stary; B Stray-Pedersen
Journal:  Sex Transm Infect       Date:  2002-12       Impact factor: 3.519

Review 3.  Beyond "safe sex"--can we fight adolescent pelvic inflammatory disease?

Authors:  Bahaa Abu Raya; Ellen Bamberger; Nogah C Kerem; Aharon Kessel; Isaac Srugo
Journal:  Eur J Pediatr       Date:  2012-07-10       Impact factor: 3.183

Review 4.  Potential mechanisms for increased HIV-1 transmission across the endocervical epithelium during C. trachomatis infection.

Authors:  Danny J Schust; Joyce A Ibana; Lyndsey R Buckner; Mercedes Ficarra; Jun Sugimoto; Angela M Amedee; Alison J Quayle
Journal:  Curr HIV Res       Date:  2012-04       Impact factor: 1.581

5.  Chemokine expression patterns differ within anatomically distinct regions of the genital tract during Chlamydia trachomatis infection.

Authors:  Heather K Maxion; Kathleen A Kelly
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

6.  Seroreactivity to Chlamydia trachomatis Hsp10 correlates with severity of human genital tract disease.

Authors:  D LaVerda; L N Albanese; P E Ruther; S G Morrison; R P Morrison; K A Ault; G I Byrne
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

Review 7.  Nitric oxide synthases and tubal ectopic pregnancies induced by Chlamydia infection: basic and clinical insights.

Authors:  Ruijin Shao; Sean X Zhang; Birgitta Weijdegård; Shien Zou; Emil Egecioglu; Anders Norström; Mats Brännström; Håkan Billig
Journal:  Mol Hum Reprod       Date:  2010-07-20       Impact factor: 4.025

8.  Prevalence of Chlamydia trachomatis infection among low- and high-risk Filipino women and performance of Chlamydia rapid tests in resource-limited settings.

Authors:  Francis Saison; Lourdes Mahilum-Tapay; Claude-Edouard E Michel; Nigel D Buttress; Elpidio Cesar B Nadala; Jose Paolo V Magbanua; Emma M Harding-Esch; M Odeta Villaruel; Lorna Canong; Rey L Celis; Helen H Lee
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

9.  Blockade of epithelial membrane protein 2 (EMP2) abrogates infection of Chlamydia muridarum murine genital infection model.

Authors:  Kaori Shimazaki; Ann M Chan; Raymond J Moniz; Madhuri Wadehra; Agnes Nagy; Catherine P Coulam; Sergey Mareninov; Eric M Lepin; Anna M Wu; Kathleen A Kelly; Jonathan Braun; Lynn K Gordon
Journal:  FEMS Immunol Med Microbiol       Date:  2009-01-12

10.  New point of care Chlamydia Rapid Test--bridging the gap between diagnosis and treatment: performance evaluation study.

Authors:  Lourdes Mahilum-Tapay; Vivian Laitila; James J Wawrzyniak; Helen H Lee; Sarah Alexander; Catherine Ison; Alison Swain; Penelope Barber; Ines Ushiro-Lumb; Beng T Goh
Journal:  BMJ       Date:  2007-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.